New Hampshire, Vermont Asked to Test Deer for COVID-19

With hunting season under way, wildlife agencies in the northeastern U.S. states of New Hampshire and Vermont have started testing for COVID-19 in white-tailed deer, as antibodies for the virus have been found in deer in other states, according to a government study.

“We collected blood samples this year during the five busiest days of the hunting season,” said Dan Bergeron, the deer biologist with the New Hampshire Fish and Game Department. “We have biologists at biological check stations and collect ages and weights annually. This year, we also had them collect blood samples.”

New Hampshire and Vermont were approached by the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service about testing the white-tailed deer population as part of its national research on the spread of COVID-19 among the species.

Maine is monitoring the tests from other states, but is not actively testing deer for COVID-19.

In its study, released in July, the inspection service tested 481 deer in Illinois, Michigan, New York and Pennsylvania and found COVID-19 antibodies in 33% of the samples.

“We do not know how the deer were exposed” to the virus, the study said. “It’s possible they were exposed through people, the environment, other deer, or another animal species.”

The study said that based on available information, the risk of deer and other animals spreading COVID-19 to people is low. It also said there were no reports of clinical illness in the deer populations surveyed, and that captive deer “experimentally infected” with the virus as part of a USDA Agricultural Research Service study didn’t show clinical signs of illness.

Source: Voice of America

Tourists Rush to South Africa Airport After Travel Bans Issued

Anxious-looking travelers thronged Johannesburg international airport and stood in long queues on Friday, desperate to squeeze onto the last flights to countries that had just shut their doors to South Africa.

Many cut short their holidays, rushing back from safaris and vineyards when Britain announced late Thursday night that all flights from South Africa and its neighbors would be banned the following day.

A flurry of nations — including the United States, Canada and several European countries — have followed suit, concerned about the discovery of a new coronavirus variant, renamed omicron, with several mutations fueling an infection resurgence in South Africa.

United Kingdom citizen Toby Reid, a 24-year-old trader in London, was camping on Cape Town’s Table Mountain with his girlfriend when the ban was announced.

“At about 5:30 a.m., we got up to see if we could catch the sunrise, and at six in the morning, we found out that there was still a possibility to get back,” he told AFP while standing in line for check-in at the Johannesburg airport just hours later.

The couple managed to grab the last two seats on an evening flight to Frankfurt, Germany.

Others who were not so lucky discussed options at ticket counters, eyes widening at proposed prices and convoluted itineraries.

“There should have been more notice,” muttered Christian Good, 50, returning to Devon, England, via Frankfurt with his husband after a beach holiday.

By chance, the pair had originally planned to return on that flight, meaning they would arrive home before mandatory hotel quarantine begins on Sunday — a requirement for citizens returning from “red list” countries.

“It’s ridiculous. We will always be having new variants,” his husband, David, exclaimed, passports in hand.

“South Africa found it, but it’s probably all over the world already,” he told AFP.

The variant has so far been detected in Belgium, Botswana, Israel and Hong Kong.

‘Tired of this’

At the airport, red “canceled” signs flashed next to London-bound flights listed on the departures board.

Other destinations were still in limbo.

A KLM flight to Amsterdam was delayed by several hours after passengers were suddenly compelled to produce negative COVID-19 results.

Rapid PCR tests were offered at the airport, with results guaranteed in two hours, but at a cost of $86, compared with the standard fee of around $52 for results delivered in roughly 12 hours.

An AFP correspondent observed Some African passport holders being told they would not be allowed to fly to Europe.

Earlier, travelers milled around a closed Air France check-in desk, waiting to find out whether an evening flight to Paris would take off as scheduled, just hours after France announced its own ban.

Among them were U.K. citizen Ruth Brown, 25, who lives in South Africa and had planned to return home for the first time since 2019 next week.

Britain kept South Africa on its red list until early October, meaning many of its citizens have been unable to travel back since the pandemic started because of the costly hotel quarantine.

They had only a few weeks of leeway before the status was revoked.

“We are tired of this situation,” said Brown, who spent the morning on the phone trying to change her flight.

“Apparently (this one) is full, but we are trying to see if we can still get seats,” she sighed.

Further down the line, Elke Hahn cradled a toddler.

She had traveled to South Africa with her partner to adopt the child and was desperate to get back to their home in Austria.

The child’s paperwork was only valid for a specific flight route that had since been changed.

“We will have to get another flight, but I don’t know how that will work,” she said.

Source: Voice of America

Fauci: US Must Study Data Before Deciding on Travel Ban Over New COVID Variant

Top U.S. infectious disease official Anthony Fauci said Friday that a ban on flights from southern Africa was a possibility and the United States was rushing to gather data on the new COVID-19 variant.

No decision to halt flights had yet been made, he said. The Wall Street Journal, citing people familiar with the matter, said White House officials were discussing potential travel restrictions on southern African countries. Those officials were expected to meet with agency officials Friday afternoon to make a recommendation, the newspaper said, without specifying which agency.

The White House referred to Fauci’s earlier comments when asked about the report and declined further comment. Global authorities have reacted with alarm to the new variant, detected in South Africa, with the European Union and Britain among those tightening border controls as scientists seek to find out if the mutation is vaccine-resistant.

The World Health Organization (WHO), however, has cautioned against hasty measures and South Africa said a British ban on flights seemed rushed.

“There is always the possibility of doing what the UK has done, namely block travel from South Africa and related countries,” Fauci said in an interview on CNN.

“That’s certainly something you think about and get prepared to do. You’re prepared to do everything you need to protect the American public. But you want to make sure there’s a basis for doing that,” he said.

“Obviously as soon as we find out more information we’ll make a decision as quickly as we possibly can.”

Fauci said U.S. scientists would speak with South African counterparts Friday about the new variant, called B.1.1.529, which has raised concern about its transmissibility and whether it might evade immune responses.

He added there was no indication the new variant was already in the United States.

Source: Voice of America

One step closer to interoperability: Applying SNOMED CT’s engine to the International Patient Summary

In 2022, SNOMED International will extend the core of SNOMED CT’s structured clinical terminology to deliver an open, standalone sub-ontology to support the scope of content within the International Patient Summary (IPS) under a Creative Commons license.

London, United Kingdom, Nov. 25, 2021 (GLOBE NEWSWIRE) — At SNOMED International’s recent October Business Meetings held in London, the organization’s governance bodies enacted a decision to extend the core of SNOMED CT’s structured clinical terminology to deliver an open, standalone sub-ontology to support the scope of content within the International Patient Summary (IPS.)

The IPS is an electronic health record extract containing essential healthcare information for use in the unscheduled, cross-border care scenario, as well as for local, regional and other care scenarios. It is a minimal, non-exhaustive set of data elements defined by ISO/EN 17269 and delivered by HL7 in both CDA and FHIR using a curated set of SNOMED CT terms.

There is a groundswell of support across all health sectors to increase the portability and usability of patient information for the purpose of safe health care delivery. In 2019, SNOMED International and HL7 International announced the formalization of a license agreement in which a relevant ‘Free for Use’ Set of SNOMED CT coded concepts would be used within the HL7 IPS. Most recently, we watched as G7 leaders collaborated to release a communique on the dire need to progress a global health interoperability agenda. IBM offers a working definition of interoperability as “the timely and secure access, integration and use of electronic health data so that it can be used to optimize health outcomes for individuals and populations.”  The G7 communique, which highlighted the importance of enabling digital healthcare systems worldwide to work together seamlessly as patients move between providers, facilities and even countries, is an impactful statement that rippled throughout the global health community. A charge taken up by the Global Digital Health Partnership, it is one SNOMED International is eager to support.

Embracing a collaborative approach, “SNOMED International has been pleased to continue to work with HL7 International and partners across Europe and beyond to define SNOMED CT content for use in the International Patient Summary,” offered SNOMED International Management Board Chair, Joanne Burns.

Continuing to act in the spirit of the IPS Freeset, SNOMED International has committed to create and release an openly available IPS sub-ontology in the first half of 2022 to enhance the existing cross border movement of information, and ultimately health system interoperability. Unlike SNOMED International’s Global Patient Set, a flat list of SNOMED CT codes and terms, an IPS sub-ontology will provide implementers with a product that can be used in healthcare solutions using the power of SNOMED CT through its query language and hierarchies for the specified scope. Use of the IPS sub-ontology will allow for more effective use of clinical data analytics and decision support, and for Artificial Intelligence applications.

Alex Elias, Chair of SNOMED International’s General Assembly, the organization’s Member governance body, has observed a significant increase in discussion regarding the IPS. “2021 has seen increased interest by governments and Health and Care organizations globally for implementing the IPS to enhance timely cross border health information flow and interoperability. This has been a primary driver in SNOMED International supporting this recent initiative to make the IPS sub-ontology openly available with SNOMED CT content.“

An organization with an extensive history and active program of collaboration, SNOMED International CEO, Don Sweete, has played a pivotal role in positioning the IPS sub-ontology as a ‘soon to be achieved’ reality. “As the G7 Health Ministers recently indicated, the importance of enabling digital healthcare systems worldwide to work together seamlessly so patients don’t suffer as they move between providers, facilities and even countries is a sentiment that has rippled throughout the global health community”, offered Sweete. He went on to state that, “continued work with fellow health standards development, national, clinical and technical entities, SNOMED International will dedicate resources to achieve the goal of digital health interoperability.” Sweete added, “equipping the IPS, already one of the best examples of international collaboration among standards bodies, with the full capability of SNOMED CT’s ontological design is a significant action that we can contribute to achieving health information access gains for patients.”

Over the coming months, SNOMED International is formalizing the steps and due diligence required to make the IPS sub-ontology available for broad release. Throughout this period, SNOMED International will continue to define the IPS sub-ontology, from content through to its release and maintenance approach for launch in the first half of 2022.

Visit SNOMED International’s IPS Sub-Ontology information page or subscribe to the organization’s news service to learn more as this initiative progresses. For additional information, contact info@snomed.org.

 

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

www.snomed.org

Attachment


Kelly Kuru
SNOMED International
comms@snomed.org

Clean Energy & Industrial Gases Group da Nikkiso Anuncia a Criação de Instalações Navais Expandidas na Coreia

TEMECULA, Califórnia, Nov. 24, 2021 (GLOBE NEWSWIRE) — O Nikkiso Clean Energy & Industrial Gases Group (Grupo), subsidiária da Nikkiso Co., Ltd (Japão), tem o orgulho de anunciar a expansão das nossas instalações em Busan na Coreia para acomodar o novo Centro Naval deles. Esta expansão representa o compromisso e apoio deles ao crescimento da indústria de construção naval coreana.

A nova e maior instalação fornece soluções marítimas de sistema completo e servirá como a base do Grupo para todas as atividades marítimas da Coreia. Como instalação unificada da Nikkiso, eles fornecerão soluções marítimas, incluindo skids de bombas, vaporizadores, controles, skids de gás combustível de alta pressão, serviços e muito mais. A instalação inclui capacidades completas de testes criogênicos, e equipe expandida de engenheiros de concepção, gerentes de produção e projetos.

A área naval tem sido um dos principais focos do Grupo, e essa expansão proporciona uma forte estrutura de suporte para o crescimento futuro. A nova instalação está perfeitamente localizada na região para apoiar os principais clientes e proporcionar crescimento antecipado do foco da indústria naval em energia limpa. Com aproximadamente 4.000 metros quadrados, a instalação está equipada para fabricar bombas criogênicas, skid de vaporizador FGSS, skids de estação LH2, skids de processo, e também contará com a mais recente instalação de teste de skid de bomba LN2. O local também inclui um centro de serviço de 342 metros quadrados.

De acordo com Daryl Lamy, Presidente da Nikkiso Cryogenic Pumps: “a Nikkiso ACD é o fornecedor preferido de skids de Gás Combustível para a indústria de construção naval coreana há mais de 20 anos! Com a nossa nova instalação de embalagem e teste de skid localizada perto dos estaleiros na Coreia, agora temos ainda maior capacidade e suporte local para atender ao substancial aumento e demanda global por novas embarcações de transporte e carga movidas a GNL.”

De acordo com Peter Wagner, CEO da Cryogenic Industries e Presidente do Grupo: “Este é um próximo passo empolgante e um marco importante para o nosso Grupo e para o mercado Naval movido a GNL, além de ser um benefício significativo para os nossos clientes da área Naval. A Nikkiso CE&IG agora pode fornecer sistemas e soluções completas para nossos clientes com suporte total da fábrica.”

Informações de Contato:

Nikkiso Clean Energy e Industrial Gases – Coreia
Matriz e Fábrica         : 83, Nosan sanup jung-ro, Gangseo-gu, Busan, 46752, Coreia do Sul
Escritório              : #1912, 170 Ganggyo jungang-ro, Yeongtong-gu, Suwon,
Gyuenggi 16614 Coreia do Sul
info@NikkisoCEIG-Korea.com

SOBRE A CRYOGENIC INDUSTRIES
A Cryogenic Industries, Inc. (agora membro da Nikkiso Co., Ltd.) fabrica equipamentos de processamento de gás criogênico projetados e plantas de processo de pequena escala para as indústrias de gás natural liquefeito (GNL), serviços de poços e gás industrial. Fundada há mais de 50 anos, a Cryogenic Industries é a empresa controladora da ACD, Cosmodyne e Cryoquip, e de um grupo comumente controlado de aproximadamente 20 entidades operacionais.

Para mais informação, visite www.nikkisoCEIG.com e www.nikkiso.com.

CONTATO COM A MÍDIA:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Nikkiso Clean Energy & Industrial Gases Group annonce la création d’une installation maritime agrandie en Corée

TEMECULA, Californie, 24 nov. 2021 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (ci-après le « Groupe »), filiale de Nikkiso Co., Ltd (Japon), est fière d’annoncer l’agrandissement de son usine de Pusan (Corée) en vue d’accueillir son nouveau centre maritime. Ce projet d’extension traduit son engagement et son soutien en faveur de la croissance du secteur coréen de la construction navale.

Le nouveau site, doté d’une envergure plus étendue, vise à produire des solutions maritimes complètes et à servir de base à l’ensemble des activités maritimes du Groupe en Corée. En qualité de site unifié de Nikkiso, l’enterprise fournira des solutions maritimes, notamment des patins de pompe, vaporisateurs, systèmes de commande, patins de gaz combustible à haute pression, ainsi que des services et bien plus encore. L’installation comprend des capacités de test cryogénique complètes et un personnel élargi comprenant des ingénieurs de conception, des responsables de production et des chefs de projet.

Le secteur maritime constitue une priorité majeure du Groupe, et cet agrandissement met à sa disposition une structure solide en vue de soutenir sa croissance future. La situation de la nouvelle installation est idéale dans la région pour desservir sa clientèle stratégique et assurer une croissance anticipée de l’accent mis par l’industrie maritime sur les énergies propres. D’une superficie d’environ 4 000 mètres carrés, le site de production est équipé pour fabriquer et produire des pompes cryogéniques, patins de vaporisateur FGSS, patins de station LH2 et patins de traitement, et il comprendra la dernière installation d’essai des patins de pompe LN2. Il comprend également un centre de service de 342 mètres carrés.

Selon Daryl Lamy, président de Nikkiso Cryogenic Pumps, « Nikkiso ACD est le fournisseur de patins pour gaz combustibles privilégié par l’industrie coréenne de la construction navale depuis plus de 20 ans ! Grâce à notre nouveau site de conditionnement et d’essai des patins localisé à proximité des chantiers navals en Corée, nous disposons désormais d’une capacité et d’un soutien local encore plus grands pour répondre à la croissance et à la demande mondiales significatives en matière de nouveaux navires de transport et de fret alimentés par GNL ».

Peter Wagner, président-directeur général de Cryogenic Industries et président du Groupe, a pour sa part déclaré : « Il s’agit d’une nouvelle étape prometteuse et d’un tournant important important pour notre Groupe et pour le marché maritime propulsé par GNL, ainsi que d’un avantage significatif pour nos clients du secteur maritime. Nikkiso CE&IG sera désormais capable de fournir des systèmes complets et de soutenir ses clients avec une solution entièrement prise en charge en usine ».

Contact :

Nikkiso Clean Energy and Industrial Gases – Corée
Siège social et usine         : 83, Nosan sanup jung-ro, Gangseo-gu, Busan, 46752, Corée
Succursale                : #1912, 170 Ganggyo jungang-ro, Yeongtong-gu, Suwon,
Gyuenggi 16614 Corée
info@NikkisoCEIG-Korea.com

À PROPOS DE CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (aujourd’hui membre de Nikkiso Co., Ltd) et ses entreprises membres fabriquent des équipements et petites usines de traitement du gaz cryogénique pour les secteurs du gaz naturel liquéfié (GNL), des services d’entretien de puits et du gaz industriel. Fondée il y a plus de 50 ans, Cryogenic Industries est la société-mère d’ACD, Cosmodyne et de Cryoquip, ainsi qu’un groupe administré en commun comptant une vingtaine d’entités opérationnelles.

Pour tout complément d’information, veuillez consulter les sites www.nikkisoCEIG.com et www.nikkiso.com.

Contact auprès des médias :
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com